No public dataset ranks every molecular target by modality separately for USPTO, EPO, CNIPA, JPO and other offices for patents filed or granted only in 2025. The defensible evidence is five modality-specific, mostly cumulative patent landscapes whose searches extend into 2025 — a best-evidence shortlist drawn from four independent sources, not a jurisdiction-by-jurisdiction league table. Counts below mix patent families and patent records and must not be compared across rows.
Blue = leading target in that landscape · pale blue = runner-up · bars are scaled within each modality card only, because units and scopes differ across landscapes. All figures are cumulative landscapes through 2025, not patents newly filed in 2025.
| Modality | Leading target | Count | Metric | Scope | Cutoff | Runner-up | Source |
|---|---|---|---|---|---|---|---|
| Antibody-drug conjugate (ADC) | HER2 | 302 | Patent families | Global | 2025-06-30 | CD79b (n = 185) | frontiersin.org |
| antibody-drug conjugate (ADC) | HER2 | 302 | patent families | global | 2025-06-30 | CD79b (n = 185) | doi.org |
| Nanobody (Nb) | PD-L1 | 177 | Patent families | Global | 2025 | PD-1 (109 patent families) | europepmc.org |
| Complement pathway inhibition (MASP-2 inhibitory antibodies) | MASP-2 | 12 | patent records | 9+ jurisdictions (WO, AU, US, CA, CN, SG, JP, MX, ES, OA) | 2025 | — | patsnap.com |
| Antibodies | GD2 | 10 | patent families | Global | 2025 | GPC2 | sites.google.com |
| Cellular immunotherapy | GD2 | 4 | patent families | Global | 2025 | PHOX2B (two patents) | sites.google.com |
Method: 6 source rows gathered in 2025 from 4 independent hosts; two duplicate ADC references to the same Frontiers study (article and DOI) are consolidated into one finding, giving 5 findings. Each count is the number of patent families (or, for MASP-2, patent records) attributed to a target in that modality’s cumulative patent landscape through its stated 2025 cutoff. Counts use different units, scopes and search methods and are not comparable across rows; no office-by-office ranking was cut — none exists in the public data found.